Skip to content
Home/Companies/Pharma/DMX Pharma

DMX Pharma

Pharma·Italy·Exited 2025·Held 3yr
Entry
2022
Hold
3yr
Exit
2025

Who owns DMX Pharma?

DMX Pharma was owned by Alto Partners SGR through Alto Capital IV (2017 vintage) from 2022 to 2025, exited via Secondary.

Buyer identity available on Pro.

Hand-verified · updated 2026-07-19

Alto Partners SGR
Investor
Alto Partners SGR
Alto Capital IV · 2017 · Small-Mid Buyout

Key facts

HQItaly
SectorPharma
StatusAcquired
Exit Type
Secondary
Buyer
MOIC
–
Exit Year
2025

More from Alto Capital IV

Other portfolio companies in the same fund.

CEI (reinvestment)
Active
MobilityItaly· 2022
Diatech
Exited 2023
BiotechItaly· 2021
to
CEI
CEI
Exited 2022
MobilityItaly· 2020
to
Bia
Exited 2022
ConsumerItaly· 2019
to
OFI
Exited 2020
PharmaItaly· 2019
to
Olimpia Splendid
Olimpia Splendid
Exited 2025
ConstructionItaly· 2019
to

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Advantice Health
Advantice Health
Active
TA AssociatesUS
Alvogen
Alvogen
Active
CVC Capital Partners
CANbridge
CANbridge
Active
General AtlanticChina
Ceva
Ceva
Exited 2025
iXO Private EquityFrance
to
curia
curia
Active
The Carlyle GroupUS
Ideal Cures Pvt. Ltd.
Ideal Cures Pvt. Ltd.
Active
TA AssociatesIndia
Track DMX Pharma

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy DMX Pharma?

6 strategic and 114financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on DMX Pharma.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue